-
Oct 9, 2024 | 
nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more
AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.
-
Aug 20, 2024 | 
digitalcommons.library.tmc.edu | Sonia Patel |Monique B. Nilsson |Xiuning Le |Tina Cascone
Home > UTHealth > GSBS > Journal Articles > 412 Clinical Cancer Reserach Humans, Vascular Endothelial Growth Factor A, Neovascularization, Pathologic, Angiogenesis Inhibitors, Neoplasms, Signal Transduction, Tumor Microenvironment DOWNLOADS Included in Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons COinS...
-
Jul 4, 2024 | 
nature.com | Sang T. Kim |Sattva Neelapu |Amishi Y. Shah |Matthew Campbell |don gibbons |Tina Cascone | +10 more
Correction to: Nature Communications https://doi.org/10.1038/s41467-022-29539-3, published online 12 April 2022In this article the funding information for Jordan Kramer was omitted and should have read, ‘J.K. is supported by the CPRIT Research Training Award CPRIT Training Program (RP210028)’. The original article has been corrected.
-
May 2, 2024 | 
targetedonc.com | Tina Cascone
Tina Cascone, MD, PhD, assistant professor, in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, delves into who was included in the phase 3 CheckMate-77T trial (NCT04025879), which assessed the perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment of patients with stage IIA to IIIB non–small cell lung cancer...
-
Apr 19, 2024 | 
targetedonc.com | Tina Cascone
Tina Cascone, MD, PhD, assistant professor, in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses background of the phase 3 CheckMate-77T trial (NCT04025879) where investigators are assessing the perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment of patients with stage IIA to IIIB non-small cell lung...
-
Mar 1, 2024 | 
jitc.bmj.com | Nikhil I. Khushalani |Patrick A. Ott |Robert Ferris |Tina Cascone
DiscussionWe report here data from two phase 1/2 trials that aimed to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of novel combinations of urelumab with cetuximab (CA186-018) or nivolumab (CA186-107). The combination of urelumab-0.1 or urelumab-8 with cetuximab-240 was well tolerated and did not appear to have additive toxicity profiles beyond the expected safety profile of cetuximab.
-
Jan 2, 2024 | 
healio.com | Mark Leiser |Mindy Valcarcel |Andrea B. Apolo |Tina Cascone
Read more You've successfully added Hematology Oncology: Genitourinary Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MADRID — Remarkable. Highly meaningful. Monumental.
-
Dec 5, 2023 | 
emjreviews.com | Jürgen Wolf |Tina Cascone
The non-small cell lung cancer (NSCLC) treatment landscape has rapidly evolved over the last two decades. The addition of immuno-oncology (I-O) and targeted agents has improved treatment options for patients with non-metastatic and metastatic NSCLC; however, there remains significant unmet need.
-
Oct 21, 2023 | 
targetedonc.com | Tina Cascone
Tina Cascone, MD, PhD, assistant professor, in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the main findings from the phase 3 CheckMate-77T trial (NCT04025879), which is evaluating the perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab among patients with stage IIA to IIIB non–small cell lung cancer (NSCLC).
-
Aug 1, 2023 | 
fal.cn | Tina Cascone
Tina Cascone, MD, PhD, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, discusses the need for increased access to genetic testing in the neoadjuvant setting for patients with lung cancer. Testing for driver mutations in non–small cell lung cancer (NSCLC) is used to identify patients who are likely to respond to a given targeted therapy.
